Hospitals and healthcare delivery systems are facing significant pressure to improve quality, reduce costs, and increase revenues. As a result, they are putting pressure on medical device manufacturers for lower prices and better outcomes. In addition, they’re introducing other restrictions – like reducing the number of suppliers, limiting physician access,…
With spiraling cost inflation and outcomes that lag many other developed economies, the US government’s healthcare insurance authority (CMS), is driving reform aimed at better quality and lower cost, and private payers are following suit. Both state and private payers are moving toward alternative payment models, like value-based payments, that…
As payers and providers continue to explore ways to reduce healthcare spending and improve patient outcomes, there is a growing trend to require more evidence of product safety and effectiveness across the product lifecycle. For manufacturers, the failure to develop such data can result in reduced formulary access and lower…
With spiraling cost inflation and lagging quality indicators driving a transition to a value-based system, public and private payers are using sophisticated tools, including health technology assessment (HTA), to evaluate the benefits of the products they buy. In this environment, companies must demonstrate both clinical efficacy and differentiated economic value…
The issue of drug pricing has become a staple of the news cycle, with fresh headlines every few weeks spotlighting either the high cost of new breakthrough drugs, or jaw-dropping price hikes for established products. While these examples represent two very different sets of issues, in the minds of consumers,…
For quite some time, providers, public and private payers, policy-makers, pharmacy benefit managers and patients have hoped the arrival of biosimilars would usher in a new era of competitive drug prices. However, as the U.S. market prepares to welcome its second biosimilar, Celltrion’s Inflectra, the future of biosimilars in this…
